-
Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer
Monday, September 27, 2021 - 10:22am | 209The FDA has accepted for review Bristol Myers Squibb & Co Inc's (NYSE: BMY) supplemental marketing applications seeking approval for two Opdivo (nivolumab) based combo regimes for esophageal squamous cell carcinoma. The application cover Opdivo / Yervoy (ipilimumab) and...
-
Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer
Friday, September 17, 2021 - 7:39am | 427Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial. Related: Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial. The trial is evaluating...
-
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
Thursday, September 16, 2021 - 11:43am | 446At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-eight patients were deemed evaluable. Zymeworks’ zanidatamab, combined with one of two chemotherapy regimens,...
-
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
Friday, June 4, 2021 - 8:14am | 432Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo (nivolumab) plus chemotherapy, and Opdivo plus Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal...
-
Merck's Keytruda/Chemo Combo Therapy Wins EU Backing For Esophageal Cancer
Monday, May 24, 2021 - 12:45pm | 203Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) combined with chemotherapy for esophageal cancer. The...
-
Coherus Shares Are Trading Higher As Toripalimab Shows Survival Benefit In Late-Stage Esophageal Cancer Study
Friday, April 23, 2021 - 10:11am | 212Coherus BioSciences Inc's (NASDAQ: CHRS) partner Junshi Biosciences reported interim analysis from JUPITER-06 Phase 3 trial evaluating toripalimab in combination with paclitaxel/cisplatin chemo as first-line treatment of advanced esophageal squamous cell carcinoma...
-
Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal Cancer
Thursday, April 8, 2021 - 8:02am | 261Bristol-Myers Squibb Co (NYSE: BMY) has announced positive topline results from Phase 3 CheckMate 648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus BMY's Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell...